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Abstract. G2-phase-arrested immature starfish oo- 
cytes contain inactive cdc2 kinase and cdc25 phos- 
phatase, and an inactivator for cdc2 kinase. In this sys- 
tem, we have studied how the regulatory balance is 
tipped toward the initial activation of cdc2 kinase. Dur- 
ing the hormone-dependent period (Guerrier, P., and 
M. Doree. 1975. Dev. BioL 47:341-348), p34  cdc2 and 
cdc25 protein are already converted, though not fully, 
to active forms, whereas the inactivators for cdc2 kinase 
and cdc25 phosphatase are able to exhibit their activi- 
ties if the hormone were removed. We produced 
"triggered oocytes," in which due to a neutralizing anti- 
cdc25 antibody, the activation of cdc2 kinase is prevented 
but cdc25 protein is phosphorylated slightly after the 
maturation-inducing hormonal stimulus. In contrast to 
control immature oocytes, in triggered oocytes the in- 
jected cdc2 kinase is not inactivated, and accordingly 
the level of cdc2 kinase activity required for meiosis 
reinitiation is much less. These results imply the pres- 
ence of a cdc2 kinase activity-independent process(es) 
that suppresses the inactivator for cdc2 kinase and ini- 
tially phosphorylates cdc25 protein, although this pro- 
cess is reversible during the initial activation of cdc2 ki- 
nase. At the most initial triggering of M-phase, the cdc2 
kinase activity-independent process might trip the 
switch leading to the initial activation of cdc2 kinase. 
Thereafter, in parallel, the cdc2 kinase-dependent feed- 
back loops described by others may cause further in- 
crease in cdc2 kinase activity. We propose that a puta- 
tive suppressor, which downregulates the inactivator 
for cdc2 kinase independently of nuclear components, 
might be a previously unrecognized component of matu- 
ration-promoting factor. 
T 
HE  cell  cycle  in  primary  oocytes  arrests  at  the 
prophase of the first meiosis which corresponds to 
the G2/M-phase border, and hence the presence of 
a G2 checkpoint is postulated specifically in oocyte mei- 
otic cell cycle (see Murray and Hunt, 1993). The release of 
oocytes from the G2 checkpoint is finally performed by a 
maturation-promoting factor (MPF).  t MPF was originally 
identified functionally as a cytoplasmic activity which rein- 
itiates the first meiosis in immature oocytes in the absence 
of  the  normal  maturation-inducing  hormonal  stimulus 
(Masui and Markert, 1971; Kishimoto and Kanatani, 1976). 
The M-phase-inducing activity contained in MPF is now 
established to be ascribed to cdc2 kinase, the active form 
of the cyclin B/p34  cd~2 complex, which governs both entry 
into and exit from M-phase in all eukaryotic cells (for re- 
views see Hunt,  1989; Doree, 1990; Nurse,  1990; Maller, 
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1991; Kishimoto, 1994). The protein kinase activity of the 
cyclin B/p34  cdce complex is controlled by phosphorylation/ 
dephosphorylation of three major residues, Thr14,  Tyrl5, 
and Thrl61,  in the p34  cd~2 subunit that is associated with 
newly synthesized cyclin B protein (for reviews see Cole- 
man and Dunphy,  1994; King et al.,  1994). Phosphoryla- 
tion of Thrl61 residue by a cdk-activating kinase (CAK), 
the cyclin  H/cdk7 complex, is indispensable for the cdc2 
kinase  activity (for reviews see Solomon, 1994; Morgan, 
1995). Phosphorylation of both Thrl4 and Tyrl5 residues 
suppresses the cdc2 kinase activity, whereas their dephos- 
phorylation results in the activation (for reviews see Cole- 
man and Dunphy, 1994; Morgan, 1995), indicating that the 
balance between the activities  of phosphorylation and de- 
phosphorylation defines the onset of M-phase. 
A  protein kinase that is possibly responsible for phos- 
phorylation  of both Thrl4  and Tyrl5 has  been recently 
demonstrated (Atherton-Fessler et al., 1994; Kornbluth et 
al., 1994), and weel/mikl kinase is known to phosphory- 
late  at  least  the  Tyrl5  residue  (Parker  and  Piwnica- 
Worms, 1992; McGowan and Russell, 1993, 1995; Mueller 
et al., 1995; Watanabe et al., 1995). A cdc25 phosphatase 
dephosphorylates  both  the  Thrl4  and  Tyrl5  residues 
(Gautier et al., 1991; Kumagai and Dunphy, 1991; Straus- 
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for review see Millar and Russell,  1992).  The activity of 
cdc25 phosphatase is increased by its phosphorylation with 
the active cdc2 kinase, indicating that cdc25 phosphatase 
and cdc2 kinase constitute a positive feedback loop for the 
amplification of cdc2 kinase activity (Kumagai and Dun- 
phy, 1992; Hoffmann et al., 1993; Izumi and Mailer, 1993). 
Similarly,  the  Thrl4/Tyrl5  kinase  is  downregulated  at 
M-phase  (Atherton-Fessler et al., 1994; Kornbluth et al., 
1994), and also weel/mikl kinase is negatively regulated 
by the phosphorylation with the mitotic inducer niml/cdrl 
kinase, the active cdc2 kinase and/or an unknown kinase 
(Coleman et al., 1993; Parker et al., 1993; Tang et al., 1993; 
Wu and Russell, 1993; McGowan and Russell, 1995; Muel- 
ler et al., 1995; Watanabe et al., 1995; for review see Cole- 
man and Dunphy, 1994). 
In spite of these individual studies in vitro, however, it is 
still unclear how these regulatory components for the cy- 
clin B/p34  cdcz complex are coordinated in vivo, in particu- 
lar how the balance between the phosphatase for activa- 
tion and the kinase for inactivation is tipped to initiate the 
feedback loops toward cdc2 kinase activation. In this con- 
text, Kuang et al.  (1991) suggested the presence of multi- 
ple forms of MPF in Xenopus eggs, and it is not yet exactly 
clear whether cdc2 kinase is the only responsible compo- 
nent of the original cytoplasmic MPF. No report has yet 
compared precisely the M-phase-inducing activity in oo- 
cytes between the original cytoplasmic MPF and the puri- 
fied cdc2 kinase (for example see Gautier et al., 1988; Labbe 
et al., 1989). In fact, the injected cdc2 kinase is inactivated 
in immature starfish oocytes (Picard et al., 1991), while the 
cytoplasmic MPF activity that is detectable upon injection 
into immature starfish oocytes requires the participation 
of nuclear components (Kishimoto et al., 1981; Picard and 
Doree, 1984; Picard et al., 1991). It would be rather antici- 
pated that the switch that leads to the initial activation of 
cdc2 kinase  in  vivo might  be  tripped by other factor(s) 
than cdc2 kinase, and that the factor(s) might constitute 
the original cytoplasmic MPF besides cdc2 kinase. 
Fully grown immature oocytes of starfish, which are ar- 
rested at G2-phase, already contain an inactive form of cy- 
clin B/p34  cdc2 complex, in which all of the Thr14, Tyrl5, 
and Thr161 residues of p34  cdc2 seem to be phosphorylated 
(see Strausfeld et al.,  1991;  Ookata  et al.,  1992).  In this 
study, we produced triggered starfish oocytes in which the 
activation  of cdc2  kinase  after  the  maturation-inducing 
hormonal stimulus was prevented by a  neutralizing anti- 
body against  cdc25 phosphatase  but  nevertheless, cdc25 
protein was slightly phosphorylated. To study the initial 
process for cdc2 kinase activation, we rapidly purified the 
active cdc2 kinase, and compared its fate upon injection in 
control immature oocytes and in triggered oocytes. The re- 
sults indicate that independently of the cdc2 kinase activ- 
ity and the nuclear components, an inactivator for cdc2 ki- 
nase, which is present in immature oocytes and appears to 
be related to the Thr14/Tyr15 kinase and/or wee1 kinase, 
was  suppressed  at  the  release  of oocytes from  the  G2 
checkpoint. Accordingly, the level of cdc2 kinase activity 
that was required for meiosis reinitiation was much less in 
triggered oocytes than in control immature oocytes. We 
propose that besides cdc2 kinase, a putative suppressor for 
the inactivator of cdc2 kinase is a previously unrecognized 
component of the original cytoplasmic MPF.  Candidates 
for the suppressor activity and for the initial activator to 
cdc25 phosphatase are discussed. 
Materials and Methods 
Starfish Oocytes and Their Extracts 
Immature oocytes or maturing oocytes at the first meiotic metaphase after 
1-methyladenine (1-MeAde) treatment were prepared from starfish, Aste- 
rina  pectinifera  as described previously (Kishimoto and  Kondo,  1986). 
Starfish oocyte extracts were obtained according to Labbe et al. (1989, 
1991).  Briefly,  10 ml of packed oocytes was Teflon/glass homogenized 
with 20 ml of a  buffer A  containing 80 mM Na-13-glycerophosphate, 20 
mM EGTA, 15 mM MgCl2 and 1 mM DTI" (pH 7.3), supplemented with 
100 mM KC1, 100 mM sucrose, 0.3 mM PMSF, and 20 Ixg/ml leupeptin. 
The mixture was centrifuged at 14,000 g for 15 rain at 4°C, followed by re- 
centrifugation of the supernatant at 140,000 g for 40 min to recover high 
speed extracts. 
Enucleated oocytes were prepared from immature oocytes as described 
previously (Kishimoto et al., 1981; Kishimoto, 1986). 
Purification of Cyclin B-Dependent cdc2 Kinase with 
p l3S"Cl-Affinity Chromatography 
Affinity chromatography with p13Su¢l-conjugated  Sepharose 4B was per- 
formed as previously described (Kusubata et al., 1992), with slight modifi- 
cations. Briefly, the high speed extracts (20 ml, 400 mg protein) containing 
cdc2 kinase from maturing starfish oocytes were recleared by centrifuga- 
tion at 140,000 g for 40 rain after thawing, and then preincubated with con- 
trol Sepharose 4B beads (3 ml) for I h at 4°C with gentle stirring. The mix- 
ture was centrifuged at low speed, and the supernatant was batch-loaded 
on  3  ml of pl3Sud-Sepharose 4B  equilibrated  with buffer B,  in which 
buffer A was supplemented with 0.01% Brij35. After a 60-min incubation 
at 4°C under gentle agitation, the pl3SUCLbeads were packed into a chro- 
matographic column. The column was washed with 15 ml of buffer B sup- 
plemented with 500 mM NaCl, followed by 15 ml of buffer B, 15 ml of 
buffer B supplemented with 30% ethylene glycol, and finally starfish cdc2 
kinase was eluted with 15 ml of buffer B containing both 500 mM NaC1 
and 50% ethylene glycol, Eluted fractions were dialyzed against buffer A 
supplemented with 10% sucrose and 0.1% NP-40 instead of 0.01% Brij35. 
For  microinjection into  oocytes, the dialyzed preparation  was concen- 
trated with Ultrafree C3TK (Millipore, Bedford, MA) in the presence of 
BSA at a final concentration of 1 mg/ml. Inactive form of the cyclin B/p34  cdc2 
complex was purified from immature starfish oocytes with the same pro- 
cedure. 
For human cdc2 kinase, HeLa cells were synchronized at M-phase with 
nocodazole after a thymidine block. The cells were homogenized with a 
low salt buffer containing 50 mM NaF, 50 mM Na-13-glycerophosphate, 1 mM 
MgCI2, 1 mM EGTA and 50 mM imidazole, pH 7.0, followed by centrifu- 
gation at 100,000 g for 1 h. Human cdc2 kinase was extracted with buffer B 
containing 400 mM NaCI from the precipitate (Hisanaga et al., 1995),  and 
was pl3~UCl-affinity purified according to Kusubata et al. (1992). 
Protein concentration was determined by bicinchoninic acid protein as- 
say reagent (Pierce, Rockford, IL) using bovine serum albumin as a stan- 
dard. SDS-PAGE was carried out by the method of Laemmli (1970)  with 
8% or 12% acrylamide gel stained with silver or Coomassie blue. 
Microinjection and Histone HI Kinase Assay 
Microinjection or transfer of MPF-containing cytoplasm into starfish oo- 
cytes was performed as described previously (Kishimoto and Kanatani, 
1976; Kishimoto, 1986). GVBD in recipient oocytes was inspected within 2 h 
after the injection. For SDS-PAGE, 10 recipient oocytes were recovered 
in 2 ~1 of seawater at an appropriate time after the microinjection, added 
with 10 t  J,1 of 2x concentrated SDS sample buffer, and immediately frozen 
in liquid N2. After boiling, the whole of each sample was applied to each 
lane of SDS-PAGE. When recipient oocytes were recovered just after the 
injection, microinjection was performed in seawater at 4°C, and pairs of 
recipient oocytes were immediately transferred to an excess amount of 
cold seawater. Then, 10 recipient oocytes were recovered finally in 2 Ixl 
of cold seawater. 
For histone HI kinase assay of microinjected oocytes, 10 recipient oo- 
cytes were rapidly washed in an excess amount of buffer A, recovered in 2 
The Journal of Cell Biology, Volume 132, 1996  126 p~l of buffer A, and immediately frozen in liquid N  2. After thawing, 8 v.l of 
a mixture containing 0.125 mM [7-32p]ATP (0.625 mCi), 6.25 mM MgCl2, 
and 1.25 mg/ml histone H1 (Boehringer Mannheim Corp., Indianapolis, 
IN) was added immediately, and the mixture was incubated for 20 min at 
20°C, Kinase reactions  were terminated by spotting 2.5-V,1 aliquots onto 
Whatman  P81 phosphocellulose  paper, and after 15 min, the filters were 
washed five times (5 rain each)  in a 200-ml solution  of 1% phosphoric 
acid. The wet filters were transferred into scintillation vials, 5 ml of ACSII 
(Amersham Corp.,  Arlington  Heights,  IL)  scintillation  fluid was added 
and the samples were counted in an Aloka scintillation counter.  Finally, 
the histone H1 kinase activity contained in an oocyte was estimated by as- 
suming that the volume of an oocyte was 4 hi, i.e., that cytoplasm was di- 
luted 250-fold in 10 Ixl of kinase reaction  mixture. For assaying cdc2 ki- 
nase preparations,  the samples were diluted  50-fold with buffer A, and 
then the histone H1 kinase activity was measured in 2 Ixl of sample as de- 
scribed above. In Figs. 3 C, 4, and 6, the histone H1 kinase activity is rep- 
resented in arbitrary  unit (a.u.) to facilitate the comparison  among these 
figures, where 100 a.u. corresponds to the histone H1 kinase activity con- 
tained in a control maturing  oocyte at the first meiotic metaphase after 
1-MeAde addition. 
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Antibodies and Immunological  Methods 
A cDNA of starfish homolog of S. pombe cdc25 was isolated,  and anti- 
starfish cdc25 antiserum was raised in rabbits by subcutaneous injection of 
bacterially expressed fragment coding the COOH-terminal 153 amino ac- 
ids of starfish cdc25. The anti-starfish cdc25 antibody was further affinity 
purified  using nitrocellulose  strips  onto which the bacterially  produced 
starfish cdc25 fragment  was transferred (see Ookata et al., 1992). The 
specificity of the anti-cdc25 antibody was confirmed by its preincubation 
with  the bacterially  produced starfish  cdc25 peptide which completely 
eliminated the reaction with the 90-kD band (see Fig. 1 D, lane 1) in lysate 
of metaphase oocytes (data not shown). For microinjection, the purified 
anti-starfish  cdc25 antibody  was  concentrated in  Tris-buffered  saline 
(TBS), pH 7.5 with Ultrafree C3TK as described above. 
A cDNA of starfish cdc2 was isolated. An anti-starfish cdc2 antiserum 
was raised  in rabbits against  a  synthetic  peptide corresponding  to the 
COOH-terminal 14 amino acids of starfish cdc2 protein (DFEGGTVLP- 
TRLGQ), and further affinity purified.  Anti-starfish  cyclin B antibody 
was raised in rabbits against bacterially produced starfish cyclin B as de- 
scribed previously (Ookata et al., 1992). Anti-phosphotyrosine antibody 
and anti-human  cdc2 antibody  against its COOH-terminal peptide were 
generous gifts from Drs.  G.  Peaucellier  (Roscoff, France) and F. Mat- 
sumura  (Rutgers  University, Piscataway, N  J), respectively. Immunoblot- 
ting  and immunoprecipitation  were performed essentially  as described 
previously (Ookata et al., 1992). For the second antibody of immunoblot- 
ting,  alkaline  phosphatase--conjugated  swine  anti-rabbit IgG  (DAKO) 
was used at a dilution of 1:400. 
Purification of  Starfish cdc25 Phosphatase  and In Vitro 
Activation of  cdc2 Kinase by cdc25 Phosphatase 
Anti-starfish  cdc25 antibody was cross-linked with protein A-Sepharose 
CIAB  (Pharmacia  LKB  Biotechnology,  Piscataway,  NJ)  by  DSS  (2, 
2-dimethyl-2-silapentane-5-sulfonate;  Pierce)  at 5 mg IgG/ml beads ac- 
cording to the manufacturer's  instructions. 15 ml of the flowthrough frac- 
tions from p13~uCl-affinity  column after the application of high speed ex- 
tracts of maturing starfish oocytes was mixed with 1 ml of the anti-cdc25 
antibody beads for 1 h at 4°C, and then the suspension was packed into a 
column. After washing the column with 10 ml of a buffer containing 500 
mM NaCl, 50 mM Tris (pH 7.5) and l  mM DTT, starfish cdc25 protein 
was eluted from its antibody-beads  with 4.5 M MgCI2 solution, pH 7.5. 3 
ml of pooled fractions were desalted with PD-10 column (Pharmacia LKB 
Biotechnology)  equilibrated  with a buffer containing  150 mM NaCl, 50 
mM Tris (pH 7.5), 1 mM DTT, and 0.1% NP-40. The cdc25 fractions were 
concentrated with Ultrafree C3TK as described above. 
To examine the effect of anti-cdc25 antibody on the in vitro activation 
of the cyclin B/p34  cdc~ complex by cdc25 phosphatase,  1.5 I~l of the puri- 
fied active cdc25 phosphatase at a concentration  of 0.05 mg/ml was prein- 
cubated for 30 rain at 2°C with 0.75 jxl of either the anti-cdc25 antibody or 
control  IgG at a concentration of 1 mg/ml, and then each mixture  was 
added with 0.75 v.l of the purified inactive form of cyclin B/p34  cd¢2 com- 
plex at a concentration of 0.05 mg/ml. After 60 rain incubation at 25°C, 2 
~1 of the incubation mixture was processed for the histone H1 kinase as- 
Figure  1.  Purification of cyclin B-dependent cdc2  kinase  with 
pl3SUd-affinity column from starfish oocytes. (A) Elution profile 
of starfish cdc2 kinase from pl3su~l-Sepharose. After preincuba- 
tion with control Sepharose beads, high speed extracts from star- 
fish  oocytes  at  the  first  meiotic  metaphase  were  mixed  with 
pl3SUC~-Sepharose equilibrated with buffer B, and then the sus- 
pension was packed into a column. Thereafter, the column (bed 
volume, 3 ml) was washed with buffer B  supplemented with 500 
mM NaCI (arrow 1), none (arrow 2), 30% ethylene glycol (arrow 
3), and finally both 500  mM NaCI and 50% ethylene glycol (ar- 
row 4). (B) Silver staining of SDS-PAGE of fractions eluted by 
buffer B containing both 500 mM NaCI and 50% ethylene glycol. 
(C) Western blots of the peak fraction of No.77 in (B) with the 
anti-starfish cdc2 antibody (lane 1) and with the anti-starfish cy- 
clin B antibody (lane 2), and of anti-cyclin B immunoprecipitate 
of the peak  fraction with the  anti-cdc2 antibody (lane 3).  (D) 
Western blots with the anti-starfish cdc25 antibody of high speed 
extracts from starfish oocytes at the first meiotic metaphase (lane 
1), p13Sucl-Sepharose adsorbed fraction (lane 2), anti-cyclin B im- 
munoprecipitate of the high  speed extracts (lane 3),  and  anti- 
cyclin B immunoprecipitate of the peak fraction eluted with both 
NaCI  and  ethylene glycol (lane  4).  Open arrowhead indicates 
rabbit IgG. 
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kinase activity  corresponds  to that at the beginning of incubation. 
Results 
Rapid Purification of  suc  l and cdc25-free Cyclin 
B-dependent cdc2 Kinase 
In the present study, we used the purified cdc2 kinase to 
dissect the initial process for cdc2 kinase activation. Since 
previous studies suggest various effects of sucl  and cdc25 
proteins on cdc2 kinase activity (see Gautier et al.,  1991; 
Kusubata  et  al.,  1992;  Zheng  and  Ruderman,  1993),  we 
first modified the  reported methods  (Labbe et  al.,  1989, 
1991; Kusubata et al., 1992)  and purified cdc2 kinase free 
of  these  proteins  from  maturing  starfish  oocytes.  High 
speed  extracts  of  maturing  starfish  oocytes  were  pre- 
cleared of proteins which bound nonspecifically to Sepharose 
4B beads, and then adsorbed to p13~ud-Sepharose  affinity 
gels (Fig. 1 A). Buffers containing either 500 mM NaC1 or 
30% ethylene glycol alone were effective for washing the 
pl3Sucl-Sepharose column, and histone H1 kinase activity 
was  almost  specifically  eluted  by  the  buffer  containing 
both 500 mM NaCl and 50%  ethylene glycol. Single step 
affinity  chromatography yielded  500--1,000-fold  purifica- 
tion with N50% recovery of the histone H1 kinase activity. 
In  peak  fractions  eluted  from  p13SU~Laffinity column, 
the major proteins were 48 and 34 kD, each of which was 
identified as cyclin B  and cdc2 protein by Western blots, 
respectively (Fig.  1, B  and C). Immunoprecipitation with 
anti-cyclin B antibodies confirmed the association of p34  cdc2 
with cyclin B. The anti-cyclin B immunoprecipitate recov- 
ered almost all the histone H1  kinase activity which was 
contained in peak fractions, as the cyclin A/p34  cdc2 kinase 
was almost undetectable during first meiotic cycle in star- 
fish oocytes (Okano, T., and T. Kishimoto, manuscript in 
preparation). 
Affinity-purified anti-starfish cdc25 antibody recognized 
a  single band in the lysate of starfish oocytes at the first 
meiotic metaphase with an apparent molecular size of 90 
kD (Fig. 1 D, lane 1). Starfish cdc25 protein was detectable 
both in the anti-cyclin B immunoprecipitate from the high 
speed  extracts  of  maturing  oocytes  and  in  the  p13  ~uct 
beads-adsorbed  fraction  before  the  washing  with  0.5  M 
NaCI, but  not in  the  anti-cyclin B  immunoprecipitate of 
the cdc2 kinase preparation which was eluted from p13  sud- 
affinity column (Fig. 1 D, lanes 2-4). Although at least a 
part of the  cyclin B/p34  ~dc2 complex was associated with 
cdc25 protein in lysates of maturing starfish oocytes as re- 
ported by Jessus and Beach (1992), cdc25 protein was re- 
leased from the complex during the washing of the p13  ~ucl- 
gels. In contrast to Labbe et al.  (1989,  1991),  p13  ~u~l was 
not  contained  in  the  present  elution  buffer  for  p13  suc~- 
affinity column. We conclude that the present preparation 
of purified cdc2 kinase was free of both cdc25  and  sucl 
proteins. 
Reversible Activation of Cyclin 
B--dependent cdc2 Kinase and cdc25 Phosphatase 
during Hormone-dependent  Period 
In immature starfish oocytes, a  maturation-inducing hor- 
mone, 1-methyladenine (1-MeAde), causes the activation 
of cyclin B/p34  c~c2 complex and induces GVBD within 30 
rain without the requirement for new protein synthesis. To 
examine the process leading to the initial activation of cdc2 
kinase,  we  took  advantage  of  the  so-called  "hormone- 
dependent  period"  (Guerrier  and  Doree,  1975),  which 
corresponds  to  a  minimum required  duration  of several 
minutes for 1-MeAde to be present in seawater to induce 
GVBD:  if 1-MeAde  is  removed before the  end  of hor- 
mone-dependent period,  oocytes fail to  undergo  GVBD. 
We monitored  the  modification  of both  cde25  and  cdc2 
proteins after 1-MeAde addition,  and followed the effect 
of the  removal of 1-MeAde  during  the  hormone-depen- 
dent period on their modification. 
When 1-MeAde was continuously present and induced 
GVBD, the electrophoretic mobility of cde25 protein was 
retarded gradually from 80 kD in immature oocytes to 90 
Figure 2.  Reversible modification  of cdc2  and  cdc25 proteins 
during  the hormone-dependent period of starfish  oocytes.  (A) 
Mobility shift of cdc25 and cdc2 proteins in starfish oocytes after 
meiosis reinitiation  by 1-MeAde. Starfish oocytes were collected 
various times after 1-MeAde  addition  (indicated  below by min), 
and  then  cdc25 protein  (upper panel), cdc2 protein  (middle 
panel), and phosphorylated Tyr-residue at 34 kD were monitored 
by Western blots. The middle band of cdc2, cdc2-M, is not associ- 
ated with cyclin B in the G2-phase arrested oocytes and metaphase 
oocytes (see Fig. 4 in Ookata et al., 1992). (B) Mobility shift of 
cdc25 and cdc2 proteins is reversed by the removal of 1-MeAde 
during the hormone-dependent period. After the addition of 1 IxM 
1-MeAde to immature starfish oocytes, 1-MeAde was removed at 
6 min, i.e., before the end of the hormone-dependent period, by 
immediate and extensive  dilution  with seawater,  resulting  in no 
induction of GVBD (T, transient;  lane 3). As a control, 1-MeAde 
was continuously present to induce GVBD at 20 min (C, continu- 
ous; lane 4). Modifications in cdc25 (upper  panel) and cdc2 (lower 
panel) proteins were monitored by the electrophoretic mobility 
shift visualized by Western blots in intact  immature oocytes  (0 
min, lane 1), and oocytes at 6 min (lane 2) or at 30 min (lanes 3 
and 4) after 1-MeAde addition. 
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panel).  This  gradual  mobility  shift  appears  to reflect  the 
levels  of phosphorylation  and  activation  of cdc25  phos- 
phatase which were reported in progesterone-treated Xe- 
nopus oocytes (Izumi et al., 1992). In accordance with the 
notion, coincidentally with the mobility shift of cdc25 pro- 
tein,  the  slowest  migrating form of starfish  cdc2 protein, 
cdc2-U, which represents the inactive form of cyclin B-asso- 
ciated p34  cdc2 with presumably phosphorylated Thrl4 and 
Tyrl5 residues (see Strausfeld et al., 1991; Fig. 4 in Ookata 
et al., 1992), disappeared, and the fastest migrating form of 
cdc2  protein,  cdc2-L,  which  represents  the  active  form 
with presumably dephosphorylated Thrl4 and Tyrl5 resi- 
dues, appeared reciprocally (Fig. 2 A, middle panel). In ac- 
cordance with  this  shift,  the  phosphorylated form of Tyr 
residue  became  undetectable  at  34  kD  in  oocyte lysates 
(Fig. 2 A, lower panel). As shown clearly in Fig. 2 B  (lane 
2;  compare  with  lane  4),  6  min  after  the  addition  of 
1-MeAde  to  immature  oocytes,  the  active  form  of cdc2 
protein,  the cdc2-L was already detectable,  and the shift- 
up of cdc25 protein,  though not full, occurred coinciden- 
tally. At this time point, the activity of histone H1 kinase 
was already in the process of increase (see Fig. 4 in Ookata 
et al., 1992). 
In contrast to continuous treatment, if 1-MeAde was re- 
moved at 6 min, GVBD failed to occur and levels of both 
cdc2 and cdc25 proteins returned within 30 min to the ini- 
tial  states  that  were  seen in immature  oocytes (Fig.  2  B, 
lane 3).  These observations indicate  that potent inactiva- 
tors for cdc2 kinase and cdc25 phosphatase, i.e., a kinase(s) 
for cdc2 protein, presumably a Thrl4/Tyrl5 kinase(s) and/ 
or weel-like kinase, and a  phosphatase for cdc25 protein, 
exhibit  their  activities  even after the partial  activation of 
cdc2 kinase and cdc25 phosphatase at least during the hor- 
mone-dependent period if 1-MeAde was removed. In this 
context, Picard et al. (1991) reported that the injected cdc2 
kinase is inactivated in immature starfish oocytes in which 
the intrinsic cdc2 kinase is not yet activated (see also Fig. 4). 
A  1  2  3  4  [3  Figure 3.  The anti-starfish  cdc25  anti- 
body neutralizes the cdc25 phosphatase 
4  ~  100-  ~  _-  o  activity and prevents the activation of 
cdc2  kinase.  (A)  The  anti-starfish 
~.  80.  cdc25 antibody prevented the in vitro 
3  ~  60-  activation of the cyclin B/p34 cat2 com- 
r~  plex  by  cdc25  phosphatase.  Inactive 
40-  form of cyclin B/p34  cdc2 complex was 
2  20-  purified  from  immature  starfish  oo- 
|  -  0,  cytes with pl3S"¢l-affinity column. Ac- 
"  tive  starfish  cdc25  phosphatase  was 
-7-  0  30  60  90  120  purified with anti-cdc25  antibody-con- 
Time  alter  1-MeAde  addition  (rain)  jugated  protein  A-Sepharose  from 
starfish  oocytes  at  the  first  meiotic 
0  0  60  0  60  (rain)  metaphase.  The  cdc25  phosphatase 
was incubated for 30 min at 2°C in the 
C  2  3  presence (bars 3 and 4) or the absence 
100  (bars 1  and 2) of the  anti-cdc25  anti- 
~.  body.  Thereafter,  the  activity  of  the 
80'  cdc25 phosphatase to activate the inac- 
tive  form of cyclin B/p34  ~°c2 complex  ~ 60  was estimated from the increase in his- 
tone H1 kinase activity after the 60-min 
40  incubation at 25°C. (B) The anti-cdc25 
•  antibody  prevents  1-MeAde-induced 
"~  20'  starfish  oocyte maturation.  The  affin- 
•  r  ity-purified  anti-starfish  cdc25  anti- 
:':'  body  was  concentrated,  and  various 
amounts of it (0 pg, 0; 1 pg, O; 5 pg, &; 
20 pg, .)  was  injected into 10 imma- 
ture starfish  oocytes each. As a control, 
20 pg of IgG (©), which was equivalent 
to the  largest  amount of the  purified 
antibody, was injected.  30 rain after the microinjection, oocytes were treated with 1 txM 1-MeAde, and then GVBD was inspected at the 
indicated times.  (C) Histone HI kinase is not activated after 1-MeAde treatment in oocytes injected previously with the anti-starfish 
cdc25 antibody. Histone H1 kinase activity was measured in intact immature starfish  oocytes (bar 1), oocytes injected with 20 pg of the 
anti-cdc25  antibody followed by 1-MeAde treatment for 30 min (bar 2; no GVBD), and control maturing oocytes at the first  meiotic 
metaphase (bar 3, M1). (D) Cdc25 protein, but not cdc2 protein, is slightly modified after 1-MeAde treatment in oocytes injected previ- 
ously with the anti-starfish cdc25 antibody. Western blots of control immature starfish  oocytes (lane 1), oocytes injected with 20 pg of 
the anti-cdc25 antibody followed by 1-MeAde treatment for 30 rain (lane 2; no GVBD), and control maturing oocytes at the first meiotic 
metaphase (lane 3) with anti-starfish  cdc25 (upper panel), anti-starfish  cdc2 (middle panel) and anti-phosphorylated Tyr (at 34 kD; lower 
panel) antibodies. In lane 4, the lysate from oocytes equivalent to lane 2 was treated with alkaline phosphatase (100 U/ml, for 60 min). In 
lane 5, after 6-dimethylaminopurine (6-DMAP; final concentration, 5 mM in an oocyte) was coinjected into immature oocytes with the 
anti-cdc25  antibody, the recipients were treated with 1-MeAde for 30 min, but no GVBD occurred. 
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Neutralizing Anti-cdc25 Antibody 
To examine the regulation of the inactivator for cdc2 kinase, 
we noticed that our preparation of the anti-starfish cdc25 
antibody, which was raised against the reported catalytic 
domain  (Galaktionov and  Beach,  1991),  neutralized  the 
activity of cdc25  phosphatase.  As shown in Fig. 3 A, the 
anti-cdc25 antibody actually prevented the in vitro activa- 
tion of the purified inactive form of cyclin B/p34  cd~2 com- 
plex by the affinity-purified cdc25 phosphatase. 
In accordance with the  in vitro effect, when immature 
starfish oocytes were injected with the purified anti-cdc25 
antibody,  and  then  treated  with  1-MeAde,  GVBD  was 
prevented in  a  manner dependent  on the  amount of in- 
jected  antibody  (Fig.  3  B).  Complete inhibition  was ob- 
served at 20 pg of the  anti-cdc25  antibody, while control 
injection of the  same amount of IgG had little effect on 
reinitiation of meiosis. The timing of GVBD was delayed 
by the injection of intermediate amount of the  antibody. 
The inhibitory effect of the anti-cdc25 antibody was over- 
come  by preincubation  with  cdc25  protein  that  was  ex- 
pressed in E. coli (data not shown). When the anti-cdc25 
antibody prevented 1-MeAde-induced GVBD in vivo, no 
increase in histone H1 kinase activity was detected (Fig. 3 
C). In these  oocytes, the cdc2-L, which represents active 
form, was undetectable,  and the phosphorylated form of 
the Tyr residue was still detectable at 34 kD (Fig. 3 D mid- 
dle and lower panels, lane 2). Therefore, the injected anti- 
cdc25  antibody  indeed  neutralized  the  activity  of cdc25 
phosphatase and thereby prevented the activation of cdc2 
kinase after 1-MeAde addition. Thus, we could produce a 
triggered oocyte of an intermediate state, in which some of 
the  pathways  initiated  by  1-MeAde  might  have  already 
been triggered (see below), but cdc2 kinase was not yet ac- 
tivated. 
In contrast to no apparent change in the electrophoretic 
mobility of cdc2 protein, a  slight retardation occurred in 
cdc25 protein in triggered oocytes (Fig. 3 D upper panel, 
compare lane 2  with  lanes 1  and 3).  The  slight mobility 
shift of cdc25 protein in triggered oocytes was reversed by 
the treatment of oocyte lysates with alkaline phosphatase, 
which also caused the  appearance of the cdc2-L and the 
disappearance of the phosphorylated Tyr residue (Fig. 3 D 
lane 4). Further, the slight mobility shift of cdc25 protein 
was prevented by coinjection of 6-dimethylaminopurine, a 
potent kinase inhibitor, with the anti-cdc25 antibody (Fig. 
3 D  lane 5).  Thus,  1-MeAde  addition  appears to induce 
some  modification,  presumably  phosphorylation,  of  the 
cdc25 protein even in the absence of the activation of cdc2 
kinase, suggesting the presence of a kinase that phosphor- 
ylates  cdc25  protein  independently  of  the  activation  of 
cdc2 kinase. However, because of the low amount of cdc25 
protein that can be recovered from the triggered oocytes, 
at present it was practically difficult to determine the phos- 
phorylation sites or to measure the activity of cdc25 phos- 
phatase in vitro. 
Suppression of  lnactivator for Cyclin B-dependent cdc2 
Kinase in Triggered Oocytes 
To examine whether the inactivator for cdc2 kinase is sup- 
pressed in triggered oocytes, subthreshold levels (see also 
Fig. 5 A) of the purified cdc2 kinase were injected into ei- 
ther  triggered  oocytes  or  intact  immature  oocytes,  and 
then  the  fate  of the  injected  cdc2  kinase  was  compared 
among these recipients. In intact immature oocytes (100 pl 
injection of starfish cdc2 kinase), when compared with the 
oocytes just after the injection, the recipient oocytes at 30 
min later contained less than half a level of histone H1 ki- 
nase activity (Fig. 4 A, bars I  and 2). This indicates, in ac- 
A  1  2  3  4 
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Figure 4.  Subthreshold  levels of cdc2 kinase are inactivated in re- 
cipient  immature starfish  oocytes  but not in triggered  oocytes. 
(A) Changes  in the histone  HI kinase  activity which was intro- 
duced by the injection of starfish cdc2 kinase. Immature starfish 
oocytes (bar 1) or triggered  oocytes  (bar 3) were injected  with 
subthreshold  levels of purified  starfish cdc2 kinase (100 pl or 75 
pl, respectively; see Fig. 5 A), and the levels of histone H1 kinase 
activity  in recipients  were measured just after the injection  (0 
min, bars 1 and 3) and 30 min later (bars 2 and 4). (B) Electro- 
phoretic mobility shift-up of human cdc2 protein which was intro- 
duced into immature starfish oocytes. Subthreshold  level of puri- 
fied  human  cdc2 kinase  was  injected  into  immature  starfish 
oocytes, and the changes of electrophoretic mobility of injected 
human cdc2 protein were detected by Western blots just after the 
injection (0 min, lane 2) and 30 min later (lane 3). Thereafter, the 
recipient  oocytes were treated with 1-MeAde  to induce GVBD, 
and the fate of human cdc2 protein in these  oocytes was moni- 
tored (lane 4). Lane 1 indicates purified human cdc2 preparation 
before the injection. (C) No modification occurs both in intrinsic 
starfish cdc2 protein and in exogenously introduced human cdc2 
protein in recipient  triggered oocytes. Subthreshold  level of puri- 
fied human cdc2 kinase was injected into triggered oocytes. West- 
ern blots of oocyte lysates with  the anti-starfish  cdc2 antibody 
(upper panel) or the anti-human  cdc2 antibody (lower  panel)just 
after the injection (0 min, lane 1) or 30 min later (lane 2). 
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that  might have contained  sucl  protein,  that  the  exoge- 
nously introduced cdc2 kinase free of sucl and cdc25 pro- 
teins was inactivated in recipient oocytes that failed to un- 
dergo GVBD. To confirm further the inactivation of the 
injected  cdc2  kinase,  subthreshold  levels  of the  human 
cdc2 kinase, which could be distinguished from the endog- 
enous starfish cdc2 protein, were injected into intact im- 
mature starfish oocytes (Fig. 4 B). The active form of hu- 
man cdc2 protein represented by the fastest mobility (see 
Atherton-Fessler et al., 1994) was converted within 30 min 
to the inactive form represented  by the slowest mobility 
(Fig. 4 B, lanes 2 and 3). The inactivation of human cdc2 
kinase  was reversible, since  the  inactive form of human 
cdc2 protein was again converted to the active form when 
oocytes were treated with 1-MeAde 30 min after injection 
(Fig. 4 B, lane 4). This reactivation indicates that the inac- 
tivation of cdc2 kinase was not due to proteolytic degrada- 
tion, and clearly demonstrates that the human cdc2 kinase, 
which had been inactivated in immature starfish oocytes, 
was still responsive to the active starfish cdc25 phosphatase. 
In contrast to intact immature oocytes, in triggered oo- 
cytes, the histone H1 kinase activity that was introduced 
by the injection of subthreshold  levels (75 pl) of starfish 
cdc2 kinase suffered neither decrease nor increase by 30 
min after injection (Fig. 4 A, bars 3 and 4). When human 
A  B  lie /  020 
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Figure 5.  The level of histone  H1 kinase  activity necessary  for 
GVBD induction  in immature starfish oocytes is much higher in 
the purified  cdc2 kinase  preparation than in cytoplasmic  MPF. 
(A)  Dose  dependency  of  GVBD  induction  on  the  injected 
amounts of cytoplasmic MPF (©) or the purified cdc2 kinase (O). 
The starfish cdc2 kinase preparation purified with pl3SUd-affinity 
column  was concentrated so that 300 pl injection  of it was just 
sufficient to induce GVBD at 100% in recipient starfish oocytes. 
Ten Asterina oocytes were injected for each point.  (B) Levels of 
histone H1 kinase activity required for either cytoplasmic MPF or 
purified cdc2 kinase to induce 100% GVBD by injection into im- 
mature starfish oocytes. The histone H1 kinase activity contained 
in cytoplasmic MPF or the cdc2 kinase preparation shown in A 
was measured, respectively. In case of cytoplasmic MPF, the his- 
tone H1 kinase activity was estimated from that contained in star- 
fish oocytes at the first  meiotic  metaphasc (see  Materials  and 
Methods). 
cdc2 kinase was injected similarly, no change was observed 
in electrophoretic mobility of either intrinsic starfish or ex- 
ogenous  human  cdc2  proteins  in  recipient  triggered  oo- 
cytes that did not undergo GVBD (Fig. 4 C). At 30 min af- 
ter injection, the active form of human cdc2 protein was 
still detected at the same level as that seen just after the in- 
jection, while starfish cdc2 protein was maintained in the 
inactive form of cdc2-U. Also,  no change in either cdc2 
protein was observed in triggered oocytes when cdc2 ki- 
nase was injected together with butyrolactone I (Kitagawa 
et al., 1993), a potent inhibitor of cdc2 kinase action (Oku- 
mura, E., unpublished). Without 1-MeAde addition, how- 
ever,  microinjection  of the  anti-cdc25  antibody  did  not 
prevent the inactivation of cdc2 kinase that was injected 
into  immature  oocytes  (data  not  shown),  excluding  the 
possibility that the anti-cdc25 antibody directly suppressed 
the inactivator for cdc2 kinase. These results indicate that 
in the absence of active cdc2 kinase, the inactivator for cdc2 
kinase  is suppressed in triggered oocytes, suggesting the 
presence of a suppressor for the inactivator of cdc2 kinase 
in triggered oocytes although the basis for this suppression 
is not yet known. 
Meiosis-reinitiating Activity of Cyclin B--dependent 
cdc2 Kinase 
Considering  that  the  inactivator  for cdc2  kinase  is  sup- 
pressed in triggered oocytes, it would be plausible that the 
levels of cdc2 kinase activity required for meiosis-reinitia- 
tion after injection might be less in triggered oocytes than 
in intact immature oocytes. To access this issue, we first 
checked whether the purified cdc2 kinase is precisely iden- 
tical with the original cytoplasmic MPF in the aspect of the 
levels of H1 kinase activity that is required for GVBD in- 
duction in intact immature oocytes. When cytoplasm taken 
from 1-MeAde-treated starfish oocytes at the first meiotic 
metaphase  was  injected  into  immature  starfish  oocytes, 
~300 pl of the cytoplasm, i.e. cytoplasmic MPF, which cor- 
responds to ~1/13  of an oocyte volume, was a minimum 
requirement to induce GVBD in recipients at a rate of al- 
most 100% (Fig. 5 A). Then, the starfish cdc2 kinase prep- 
aration purified with pl3SU~l-affinity  column was concen- 
trated so that its injection of 300 pl was just enough to induce 
100%  GVBD in recipient starfish oocytes (Fig. 5 A). The 
percentage of oocytes that underwent  GVBD  decreased 
when smaller volumes of either purified cdc2 kinase or cy- 
toplasmic MPF were injected.  Despite similar activity in 
oocytes, however, cytoplasmic MPF and purified cdc2 ki- 
nase preparations contained extremely different levels of 
histone H1 kinase activity. In the minimum volume (300 
pl) required to induce 100% GVBD in recipients, the puri- 
fied starfish cdc2 kinase preparation had an N10-fold higher 
level of histone H1 kinase activity than that contained in 
cytoplasmic MPF  (Fig.  5  B).  Similar levels of difference 
were still observed when cytoplasmic MPF was coinjected 
with the buffer for cdc2 kinase preparation (data not shown), 
or when histone H1 kinase activity of the purified cdc2 ki- 
nase was measured immediately after the injection into im- 
mature oocytes (Fig. 6 A, compare bars 3 with 1), indicat- 
ing that the discrepancy is not due to the difference between 
oocyte homogenates and purified preparations. 
After injection of either cytoplasmic MPF or the starfish 
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Figure 6.  The level of cdc2 kinase activity required for GVBD in- 
duction  is less in triggered  oocytes than in intact immature oo- 
cytes in spite of the lack of amplification. (A) Changes in histone 
H1 kinase activity at GVBD after injection with either cytoplas- 
mic MPF or cdc2 kinase into intact immature starfish oocytes or 
triggered  oocytes. Either cytoplasmic MPF (bar 1) or the starfish 
cdc2 kinase preparation indicated in Fig. 5 A (bar 3 for 300 pl; bar 
5 for 150 pl) was injected into either intact immature starfish oo- 
cytes (bars I and 3) or triggered oocytes (bar 5). Levels of histone 
H1 kinase  activity contained in these recipients  were measured 
just after the injection  (0 rain; bars 1, 3, and 5) or at the time of 
GVBD after injection  (30 min,  bars 2, 4, and 6).  (B) Intrinsic 
cdc25 phosphatase and cdc2 kinase are activated at GVBD after 
injection  into immature starfish  oocytes with either cytoplasmic 
MPF or purified human cdc2 kinase. When injection of either cy- 
toplasmic MPF (lanes I and 2) or human cdc2 kinase (lanes 3 and 
4) induced  GVBD in intact  immature starfish  oocytes, mobility 
shifts in starfish cdc2 (upper panel) and cdc25 (lower  panel) pro- 
teins, and the presence or absence of phosphorylated Tyr-residue 
at 34 kD (middle panel) were monitored in recipient  starfish oo- 
cytes by Western blots. The upper band of cdc2, cdc2-U, which 
was present just after the injection  (0 min, lanes I  and 3), disap- 
peared and the lower band of cdc2, cdc2-L, appeared reciprocally 
at the time of GVBD after injection  (30 min, lanes 2 and 4). (C) 
No modification occurs both in intrinsic starfish cdc2 protein and 
in exogenously  introduced  human cdc2 protein in recipient  trig- 
gered oocytes at GVBD. The purified human cdc2 kinase was in- 
cdc2 kinase  preparation, so-called amplification, i.e.,  the 
activation of the cyclin B/p34  ode2 complex and cdc25 phos- 
phatase which were already present as an inactive form in 
recipient immature oocytes, occurred: at the time of GVBD 
after the injection, histone H1 kinase activity increased by 
similar amount in both cases of recipients (Fig. 6 A, bars 2 
and 4).  Regardless of whether cytoplasmic MPF or puri- 
fied human cdc2 kinase induced GVBD, the starfish cdc2-U 
and the phosphorylated form of Tyr residue at 34 kD dis- 
appeared, and the starfish cdc2-L, which represents the ac- 
tive form, appeared in both recipient oocytes after GVBD 
(Fig. 6 B, upper and middle panels, lanes 1-4).  In accor- 
dance  with  these,  the  electrophoretic  mobility  of cdc25 
protein was retarded to the same level in both recipients 
(Fig. 6 B, lower panel, lanes 1-4), indicating the activation 
of intrinsic cdc25 phosphatase. 
By contrast, in triggered oocytes, microinjection of 150 
pl of the purified starfish cdc2 kinase, which corresponds 
to only one-half the level of histone H1 kinase activity re- 
quired  for intact  immature oocytes, was sufficient to in- 
duce 100%  GVBD, even though no appreciable increase 
of histone HI kinase activity was observed in recipient oo- 
cytes (Fig. 6 A, bars 5 and 6). The lack of amplification in 
recipient triggered oocytes was confirmed by the presence 
of starfish cdc2-U and the absence of starfish cdc2-L when 
GVBD was induced by the injection of human cdc2 kinase 
(Fig. 6 C upper panel). In this case, no change was also ob- 
served in  human cdc2 protein  (Fig.  6 C lower panel). In 
contrast that  GVBD was completed within  30  min  after 
1-MeAde addition in control immature oocytes, the timing 
of GVBD was delayed in  triggered oocytes with the  de- 
crease in injected amounts of cdc2 kinase (data not shown). 
The observed correlation may reflect the actual response 
of oocytes to the injected cdc2 kinase, since neither ampli- 
fication nor loss of cdc2 kinase activity occurs in triggered 
oocytes. 
These  observations  suggest  that  the  discrepancy  be- 
tween cytoplasmic MPF  and  purified cdc2  kinase  in  the 
levels of histone H1 kinase activity required for GVBD is 
at  least partially explained  by the  ability of cytoplasmic 
MPF to suppress the inactivator of cdc2 kinase. Since pre- 
vious studies  (Kishimoto et  al.,  1981;  Picard  and  Doree, 
1984)  suggest the involvement of germinal vesicle compo- 
nents  in  the  MPF  activity that  is detectable  by injection 
into immature starfish oocytes, we examined whether the 
suppression of the inactivator for cdc2 kinase depends on 
the  presence of germinal vesicle. We  applied the  proce- 
dure for the production of triggered oocytes to immature 
oocytes that had been enucleated previously. In these trig- 
gered enucleated  oocytes as well, sub-threshold  levels of 
the injected human cdc2 kinase were not inactivated (Fig. 
7), while the inactivation of cdc2 kinase was observed in 
control  enucleated  immature  oocytes  (data  not  shown). 
These facts imply that in triggered oocytes, the  suppres- 
sion activity for the inactivator of cdc2 kinase does not de- 
pend on germinal vesicle components. 
jected into triggered  oocytes to induce GVBD as indicated  in A. 
Western blots  of oocyte lysates with the anti-starfish  cdc2 anti- 
body  (upper panel) or  the  anti-human  cdc2  antibody  (lower 
panel) just after the injection (0 min, lane 1) or 30 min later (lane 2). 
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cdc2 kinase is suppressed in- 
dependently of germinal ves- 
icle in triggered  oocytes. Im- 
mature starfish  oocytes were 
enucleated,  injected  with the 
neutralizing  anti-cdc25  anti- 
body, and then treated with  1-MeAde.  These oocytes were in- 
jected with  subthreshold  level  of human  cdc2  kinase.  Human 
cdc2 protein in recipients  was monitored by Western blots just 
after its injection (0 min) or 30 min later. Note that no change oc- 
curs in the lower band of human cdc2 protein. 
Discussion 
Components  Controlling the Oocyte G2 Checkpoint 
By using the purified cdc2 kinase free of sucl and cdc25 pro- 
teins, and the neutralizing anti-cdc25 antibody, the present 
study demonstrates clearly that the activity of cdc2 kinase 
at the oocyte G2 checkpoint is regulated by a network that 
includes at least the following components: an inactivator 
for cdc2 kinase, a suppressor of this inactivator, cdc25 phos- 
phatase, a putative kinase which phosphorylates cdc25 pro- 
tein independently of cdc2 kinase, and a phosphatase which 
dephosphorylates cdc25  protein  (see Fig.  8).  Candidates 
for these activities are as follows. 
The  inactivator  for cdc2  kinase  might include  at  least 
weel-like  kinase  and/or  the  Thrl4/Tyrl5  kinase.  In  the 
suppression of weel-like kinase, Devault et al. (1992) sug- 
gest the  involvement of cyclin A-dependent  kinase.  But, 
this possibility is excluded in the present suppression, be- 
cause cyclin A  is undetectable until first meiotic metaphase 
in starfish oocytes (Okano, T., and T.  Kishimoto, manu- 
script in preparation). Nonetheless, dual type of phosphor- 
ylation-dependent  inactivation is suggested in  the  down- 
regulation  of  weel  kinase  at  M-phase  (Coleman  et  al., 
1993; Tang et al., 1993; for review see Coleman and Dun- 
phy, 1994). Fission yeast niml/cdrl kinase phosphorylates 
its COOH-terminal domain, while M-phase extracts of Xe- 
nopus  eggs  contain  at  least  two  responsible  kinases  for 
NH2-terminal domain  (Mueller  et al.,  1995);  cdc2 kinase 
showing direct effect and a distinct kinase related to a pu- 
tative  MPM-2  epitope  kinase  (ME  kinase)  (Kuang  and 
Ashorn, 1993;  Westendorf et al., 1994). However, human 
weel kinase is phosphorylated but not inactivated by cdc2 
kinase  (Watanabe et al.,  1995),  and in  the  present study 
the suppression of the inactivator for cdc2 kinase was ac- 
complished in the absence of cdc2 kinase and cdc25 phos- 
phatase  activities  (Figs.  3  and  4).  On  the  other  hand,  at 
present the suppression mechanism of the Thrl4/Tyrl5 ki- 
nase is unclear  except that  its activity is  undetectable  at 
M-phase (Atherton-Fessler  et al.,  1994;  Kornbluth et al., 
1994).  Taken together, the putative suppressor for the in- 
activator of cdc2 kinase would be an unknown inhibitory 
kinase, possibly related to the ME kinase. 
The slight mobility shift-up of cdc25 protein, which was 
observed in triggered oocytes, is first revealed at the initia- 
tion of M-phase in vivo, but in the absence of the activa- 
tion of cdc2 kinase. As a candidate for the responsible ki- 
nase, the possibility of cyclin A--dependent cdc2 kinase is 
again excluded  due  to  its  absence  (see  above). In inter- 
phase  extracts  of Xenopus  eggs,  phosphatase  inhibitors 
cause phosphorylation and activation of cdc25 phosphatase 
in the absence of cdc2 kinase activity (Izumi et al.,  1992; 
Kumagai and Dunphy, 1992; Clarke et al., 1993; Izumi and 
Mailer,  1995).  As  a  candidate  for a  cdc25  protein-phos- 
phorylating  kinase  that  is  distinct  from cdc2  kinase,  the 
ME kinase has been again suggested (Kuang and Ashorn, 
1993;  Kuang et al., 1994;  Izumi and Mailer, 1995). Taken 
together,  an unknown  kinase, presumably related  to the 
ME kinase, would be involved in the initial phosphoryla- 
tion of cdc25 protein at the release from G2-phase arrest, 
while a  type-2A phosphatase might counteract this phos- 
phorylation  (see  Izumi et  al.,  1992;  Clarke  et  al.,  1993; 
Izumi and Mailer, 1995). 
In Vivo Coordination for the lnitial Activation of cdc2 
Kinase at the Release from G2-Phase Arrest of Oocytes 
How are the  regulatory balances coordinately tipped to- 
Figure 8.  A model for the initial activation of cdc2 kinase in vivo 
at the  release from the oocyte G2-phase checkpoint.  The G2- 
phase arrest of immature oocytes is ensured by an active form of 
an inactivator of cdc2 kinase. 1-MeAde treatment of oocytes causes 
the release from the G2-phase arrest by two pathways that are in- 
dependent of the cdc2 kinase activity: In one pathway, the activ- 
ity of the inactivator  of cdc2 kinase is downregulated  by its sup- 
pressor before the cdc2 kinase  activation,  whereas in the other 
pathway,  cdc25 undergoes  an  initial  cdc2  kinase-independent 
phosphorylation by  an  initial  kinase  that  may activate  cdc25 
phosphatase  activity.  Activation  of these  two  pathways in  re- 
sponse to the maturation-inducing  stimulus,  1-MeAde, results in 
the initial increase  in cdc2 kinase activity by simultaneously  re- 
moving an inhibitor of the kinase and stimulating  the activation 
of previously  inactive  cyclin  B/p34  ~2  complexes.  Further  in- 
crease in cdc2 kinase activity may be through the positive amplifi- 
cation loop described  by others (see text for details). The inacti- 
vator of cdc2 kinase seems to include the Thrl4/Tyrl5 kinase for 
p34  cd~2 and/or weel/mikl kinase. Although the components of ac- 
tivities involved in the suppressor for the inactivator of cdc2 ki- 
nase and the initial phosphorylation of cdc25 protein are not yet 
known, it is likely that they include unknown protein kinases. Ac- 
cordingly,  the upregulation  of these protein kinases  and/or the 
downregulation  of phosphatases that counteract these kinases, 
presumably type-2A phosphatases, contribute to the suppressor 
and the initial  kinase  activity. We propose that, in addition  to 
cdc2 kinase activity, the activity of the suppressor for the inacti- 
vator of cdc2 kinase is also a component of MPF detected by cy- 
toplasmic transfer experiments.  See text for details. 
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of the production of triggered oocytes, the present study 
clearly brings the answer to this question at least on the re- 
lease from the G2 checkpoint of oocytes. As summarized 
in Fig. 8, before the initial activation of cdc2 kinase, its in- 
activator is actually downregulated by the suppressor, and 
coincidentally cdc25 phosphatase may be upregulated by 
its initial kinase. It may be possible that both the suppres- 
sor and the initial kinase are the same ME kinase that is 
under the control of 1-MeAde stimulus. 
Alternatively, the present study indicates that a  phos- 
phatase,  presumably type-2A, counteracts  the  unknown 
kinase in the initial phosphorylation of cdc25 protein (see 
above in relation to Fig. 2 B). The type-2A phosphatase is 
also involved in the upregulation of weel kinase (Muller 
et  al.,  1995;  McGowan  and  Russell,  1995). These imply 
that  the  downregulation  of type-2A phosphatase  would 
cause both the upregulation of cdc25 phosphatase and the 
downregulation of weel kinase, serving as both the initial 
kinase of cdc25 protein and the suppressor for the inacti- 
vator of cdc2 kinase. Thus, either the upregulation of a pre- 
sumed ME kinase or the downregulation of a  presumed 
type-2A phosphatase, or both might initiate the cdc2 ki- 
nase activation at the release from the oocyte G2 check- 
point. 
The present result implys that both the inactivator of 
cdc2 kinase and the phosphatase of cdc25 protein are still 
able to exhibit their activities during the hormone-depen- 
dent period even after the activation of cdc2 kinase has 
been already initiated (Fig. 2 B). The hormone-dependent 
period might correspond to a duration before both regula- 
tors lose their activity. These notions do not suggest that 
both the suppressor for the inactivator of cdc2 kinase and 
the  initial kinase  of cdc25 protein have completed their 
functions before the initial activation of cdc2 kinase, but 
rather that both accomplish their functions in parallel with 
the activation of cdc2 kinase. Taken together, there might 
be two distinct processes for the cdc2 kinase activation: (1) 
a cdc2 kinase activity-independent one including both the 
suppressor for the inactivator of cdc2 kinase and the initial 
kinase  of cdc25 protein, and  (2)  a  cdc2 kinase  activity- 
dependent  one  including  the  feedback  loops  positively 
with cdc25 phosphatase (Hoffmann et al., 1993; Izumi and 
Mailer, 1993)  and negatively with the inactivator of cdc2 
kinase (see Mueller et al., 1995). At the most initial trig- 
gering of M-phase,  the cde2 kinase activity-independent 
process might trip the switch that leads to the initial activa- 
tion of cdc2 kinase, and thereafter, both processes might 
proceed in parallel possibly during the  hormone-depen- 
dent period. After such an initial step, feedback that de- 
pends on the activity of cdc2 kinase might further increase 
the cdc2 kinase activity. 
Responsible Components  for Cytoplasmic  MPF 
MPF was originally identified as a cytoplasmic activity that 
reinitiates meiosis upon injection into immature oocytes. 
Cdc2 kinase is without doubt an essential component of 
cytoplasmic MPF (Lohka et al., 1988; Gautier et al., 1988, 
1990;  Labbe  et  al.,  1989;  present  study).  If cdc2 kinase 
were the only responsible component for the original cyto- 
plasmic MPF, the level of histone H1 kinase activity that is 
required for the induction of meiosis reinitiation would be 
similar between cytoplasmic MPF and cdc2 kinase. In this 
issue, however, our present data (Fig. 5 B) clearly demon- 
strates the discrepancy, indicating that other component(s) 
than cdc2 kinase is responsible for MPF activity (see also 
Picard et al., 1991). 
What  is  a  responsible  component(s)  for  cytoplasmic 
MPF? Comparison of control immature oocytes with trig- 
gered oocytes (Fig. 6 A, bars 3 and 5) indicates that the level 
of cdc2 kinase  required for meiosis reinitiation is much 
less when the inactivator of cdc2 kinase is suppressed. In 
the absence of the suppression, a higher level of cdc2 ki- 
nase might be necessary to overcome the inactivator and 
to induce meiosis reinitiation. If so, the suppressor for the 
inactivator of cdc2 kinase would be a possible candidate 
for the responsible component of cytoplasmic MPF. 
In starfish oocytes, previous studies indicate that germi- 
nal vesicle contents are required for the cytoplasmic MPF 
activity that is detectable upon injection into immature oo- 
cytes (Kishimoto et al.,  1981; Picard and Doree, 1984), in 
spite that after 1-MeAde addition enucleated oocytes ex- 
hibit similar levels of histone H1 kinase activity as nucle- 
ated oocytes (Picard et al., 1988). In this context, we could 
produce triggered oocytes even from previously enucle- 
ated immature oocytes (Fig. 7), implying that the inactiva- 
tor of cdc2 kinase is suppressed independently of the pres- 
ence of germinal vesicle. We conclude that  the  present 
suppressor  for the  inactivator of cdc2 kinase  is  distinct 
from the germinal vesicle components required for MPF 
activity and is a previously unrecognized component of MPF. 
Cdc25 phosphatase alone exhibits MPF activity (Gautier 
et al.,  1991;  Kumagai and Dunphy, 1991)  and associates 
with cdc2 kinase (Jessus and Beach, 1992; present study), 
suggesting  that  cdc25  phosphatase  may constitute cyto- 
plasmic MPF. However, the cdc2 kinase level that was re- 
quired for meiosis reinitiation was much less in triggered 
oocytes where cdc25 phosphatase was prevented than in 
control immature oocytes where it was able to be activated 
(Fig. 6 A, bars 3  and 5). Thus, cdc25 phosphatase would 
not be a necessary but rather a supplementary component 
for cytoplasmic MPF. 
In summary, we propose a hierarchy for the components 
of cytoplasmic MPF: the minimal essential component is 
cdc2 kinase; the secondary responsible component is the 
suppressor for the inactivator of cdc2 kinase; and the sup- 
plementary component is cdc25 phosphatase. 
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